Gunnar Folprecht

Summary

Country: Germany

Publications

  1. ncbi Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting
    Gunnar Folprecht
    Medical Department I, Carl Gustav Carus University Hospital of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Nat Clin Pract Oncol 2:578-87. 2005
  2. ncbi Patients' perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population
    Marika Mende
    Medical Department I, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
    BMC Cancer 13:66. 2013
  3. ncbi Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
  4. ncbi Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Clin Cancer Res 14:215-23. 2008
  5. ncbi Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
  6. ncbi Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Gunnar Folprecht
    University Hospital Carl Gustav Carus, Medical Department I University Cancer Center, Dresden, Germany
    Lancet Oncol 11:38-47. 2010
  7. ncbi [Current medicinal treatment of metastasized colorectal carcinoma]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, Dresden, Germany
    Chirurg 81:507-15. 2010
  8. ncbi [Neoadjuvant therapy concepts for liver metastases]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 82:989-94. 2011
  9. ncbi [New therapy options in colorectal carcinoma]
    G Folprecht
    Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Dresden
    Ther Umsch 61:373-8. 2004
  10. ncbi The role of new agents in the treatment of colorectal cancer
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Oncology 66:1-17. 2004

Collaborators

Detail Information

Publications23

  1. ncbi Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting
    Gunnar Folprecht
    Medical Department I, Carl Gustav Carus University Hospital of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Nat Clin Pract Oncol 2:578-87. 2005
    ....
  2. ncbi Patients' perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population
    Marika Mende
    Medical Department I, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
    BMC Cancer 13:66. 2013
    ..We evaluated palliative cancer patients' reported outcomes (PROs) for toxicity and investigated the survival threshold for which they would repeat chemotherapy (CTx)...
  3. ncbi Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
    ....
  4. ncbi Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Clin Cancer Res 14:215-23. 2008
    ..Complete pharmacokinetic sampling and tumor biopsies, when feasible, were conducted...
  5. ncbi Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
    ..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
  6. ncbi Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Gunnar Folprecht
    University Hospital Carl Gustav Carus, Medical Department I University Cancer Center, Dresden, Germany
    Lancet Oncol 11:38-47. 2010
    ..Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the effectiveness of cetuximab combined with chemotherapy in this setting...
  7. ncbi [Current medicinal treatment of metastasized colorectal carcinoma]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, Dresden, Germany
    Chirurg 81:507-15. 2010
    ..g. neoadjuvant treatment of non-resectable liver metastases), tumor symptoms which urgently require a tumor response and comorbidities...
  8. ncbi [Neoadjuvant therapy concepts for liver metastases]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 82:989-94. 2011
    ..Operations should be planned as soon as resectability is achieved because a longer therapy will increase morbidity and because of uncertainty over the approach to patients with complete remission...
  9. ncbi [New therapy options in colorectal carcinoma]
    G Folprecht
    Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Dresden
    Ther Umsch 61:373-8. 2004
    ..The additional therapy with the VEGF-antibody bevacizumab prolongs survival by more than 4 months compared to chemotherapy alone. The EGF-receptor antibody cetuximab is an effective therapy after progression with irinotecan...
  10. ncbi The role of new agents in the treatment of colorectal cancer
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Oncology 66:1-17. 2004
    ..The monoclonal EGF receptor antibody cetuximab alone and in combination with irinotecan is active in second-line treatment. The VEGF antibody bevacizumab prolongs survival when given in combination with 5-FU/FA and irinotecan...
  11. ncbi [Principles of postoperative therapy in rectal carcinoma]
    G Folprecht
    Medizinische Klinik und Poliklinik I, , Dresden, Germany
    Chirurg 75:32-7. 2004
    ..These drugs should not be used outside clinical trials. Elderly patients benefit from adjuvant therapy to the same extent as younger patients and should receive adjuvant radiochemotherapy, if no contraindication exists...
  12. ncbi Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer
    G Folprecht
    University Hospital Carl Gustav Carus, Dresden, Germany
    Cancer Treat Res 134:425-40. 2007
  13. ncbi Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    G Folprecht
    University Hospital, Dresden, Germany
    Ann Oncol 17:450-6. 2006
    ..CONCLUSIONS: Addition of cetuximab to weekly infusional 5-FU/FA plus irinotecan is safe and first data suggest a promising activity. The 5-FU dose of 1500 mg/m(2) is recommended for further studies...
  14. ncbi Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary
    Katharina Schuette
    University Hospital Carl Gustav Carus, Dresden, Germany
    Onkologie 32:162-6. 2009
    ..We performed a phase II study with oxaliplatin (OX) and capecitabine (CAP) as first-line treatment for patients with histo-or cytologically proven adeno- or undifferentiated CUP...
  15. ncbi Current perspectives in the treatment of metastatic colorectal cancer
    C H Kohne
    University Hospital Dresden, Medical Department I, Germany
    Ann Oncol 15:iv43-53. 2004
  16. ncbi Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
    G Folprecht
    University Hospital Dresden, Germany
    Ann Oncol 16:1311-9. 2005
    ..Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams...
  17. ncbi Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
    Jana Babatz
    Medizinische Klinik und Poliklinik I, , Fetscherstr. 74, 01307, Dresden, Germany
    Cancer Immunol Immunother 55:268-76. 2006
    ..CONCLUSION: Vaccination with CEAalt-pulsed DCs derived from immunomagnetically isolated CD14+ monocytes efficiently expand peptide-specific CD8+ T lymphocytes in vivo and may be a promising alternative for cancer immunotherapy...
  18. ncbi Colorectal liver metastases: an update on palliative treatment options
    Ralf Konopke
    Department of General, Thoracic and Vascular Surgery, University of Technology, Dresden, Germany
    J Gastrointestin Liver Dis 21:83-91. 2012
    ..The present review provides an overview of current colorectal liver metastasis treatment when resection is not an option. This review gives the basis for an interdisciplinary decision making process for the treatment of liver metastasis...
  19. ncbi Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
    G Folprecht
    University Hospital, Dresden, Germany
    Ann Oncol 15:1330-8. 2004
    ..Infusional 5-FU was shown to be more effective than bolus 5-FU in both age groups. Therefore, standardized palliative chemotherapy should generally be offered to elderly patients and they should not be excluded from clinical trials...
  20. ncbi Chemotherapy in elderly patients with colorectal cancer
    Claus Henning Köhne
    Klinik für Onkologie Hämatologie, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Oncologist 13:390-402. 2008
    ..The management of frail elderly patients and those with a short life expectancy should be focused on palliation, while fit elderly patients can receive aggressive therapy in a similar fashion to younger patients...
  21. ncbi Role of new agents in the treatment of colorectal cancer
    Claus Henning Köhne
    Klinik for Oncology Hematology, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Surg Oncol 13:75-81. 2004
    ..e. Cetuximab, Tyrosine kinase inhibitors and Vascular endothelial growth factor receptor inhibitors. This article reviews the above mentioned drugs and includes a recommended approach to chemotherapy in metastatic colorectal cancer...
  22. ncbi Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization
    Knut Liepe
    Department of Nuclear Medicine, Hospital Kassel, Mönchebergstr 41 43, 34125 Kassel, Germany
    Jpn J Clin Oncol 37:942-50. 2007
    ..This paper describes the feasibility of intra-arterial high-activity administration of (188)Re-microspheres...
  23. ncbi Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
    Focke Ziemssen
    Acta Ophthalmol Scand 85:573-4; author reply 574-5. 2007